Cleveland Clinic Cancer Center oncologist Nathan Pennell MD, PhD, and other experts provide guidance on caring for lung cancer patients during the COVID-19 pandemic
A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
Cleveland Clinic researchers have trained an advanced computer network to find subtle radiation sensitivity features in the CT scans of individual lung cancer patients that can predict the likelihood of successful radiotherapy outcomes. The network can generate a personalized radiation dose plan that reduces the probability of treatment failure to less than 5%.
A lung cancer survivor with abnormal stricture of the trachea and bronchus receives a customized, 3D-printed silicone stent, an approach pioneered at Cleveland Clinic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Can metastases to the lung occur from cancers that were treated several years ago?
A study recently published in Lancet Oncology found ALT-803 + nivolumab safe and with early signs of efficacy in patients with mNSCLC considered PD-1-treatment resistant.
Preliminary data from the first prospective clinical trial shows higher blood-based tumor burden works as biomarker for effective atezoli-zumab treatment in non-small cell lung cancer patients.
A study presented at the USCAP 2018 Annual Meeting finds that insulinoma-associated protein 1 (INSM1) is a reliable marker for the diagnosis of neuroendocrine lung tumors, including small-cell lung carcinoma.
A computer-assisted analysis of digital tissue microarray slides could soon help identify which NSCLC patients are likely to face early recurrence.
In addition to determining the probability of finding N2 or N3 disease on EBUS-TBNA the model is also able to predict the presence of mediastinal disease when EBUS-TBNA nodal sampling is negative.